Pfizer and BioNTech have teamed up with a South African drugmaker that will help produce their COVID-19 vaccine for distribution throughout Africa.

Cape Town-based Biovac will manufacture finished vaccine doses beginning in 2022, with annual production expected to reach more than 100 million doses, the companies said.

Pfizer has had a working relationship since 2015 with Biovac, which manufactures and distributes Pfizer’s Prevenar 13 pneumococcal vaccine.